Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > New results?
View:
Post by westcoast1000 on Oct 05, 2022 3:30pm

New results?

Let us hope (and it is reasonable expect) that these presentations offer more information and results than the three person trial result announced last spring.
Comment by Spdstr on Oct 05, 2022 4:31pm
Oncolytics will host a key opinion leader (KOL) webinar to discuss the current treatment landscape and unmet medical need in pancreatic cancer, as well as the interim GOBLET study results that will be presented at the SITC conference
Comment by Buckhenry on Oct 05, 2022 4:45pm
they will say that pela is well tolerated in lab rats and we need further studies.......
Comment by askretka on Oct 06, 2022 3:11am
Quote is from August Transcript, We should have new patient results and follow-up on original 3 patients. They usually wouldn't schedule announcements of an abstract and KOL afterwards to announce bad results. I'm pretty sure they have some more good results progress on the next set of patients and already know where things are heading ...more  
Comment by jimsenior on Oct 06, 2022 7:37am
I think the following may address CPI alone with chemotherapy.. Search: Combination Immunotherapy for Pancreatic Cancer: challenges and considerations.
Comment by cardu on Oct 06, 2022 10:36am
If the results show an extension of the 3 person tumour reduction published last sping, it will be explosive. Also the mice results that someone called a CURE!
Comment by inthno on Oct 06, 2022 11:01am
The 4th quarter should for sure show some interesting insights as to exactly where onc is going or will be in the next few months at the most. What would be nice is if the panc results showed durability on the first 3 patients and more partial responses on the other patients that should be reported on at the time. Then the game is a foot as they say. Roche will not wait if they are what we are all ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities